Torsdag 26 December | 21:20:01 Europe / Stockholm

Kalender

Tid*
2025-06-03 07:00 Bokslutskommuniké 2025
2025-03-03 07:00 Kvartalsrapport 2025-Q3
2025-01-20 N/A Extra Bolagsstämma 2025
2024-12-04 - Kvartalsrapport 2025-Q2
2024-09-26 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2024-09-25 - Årsstämma
2024-08-29 - Kvartalsrapport 2025-Q1
2024-05-30 - Bokslutskommuniké 2024
2024-02-29 - Kvartalsrapport 2024-Q3
2023-12-04 - Kvartalsrapport 2024-Q2
2023-10-04 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2023-09-27 - Årsstämma
2023-08-31 - Kvartalsrapport 2024-Q1
2023-06-08 - Bokslutskommuniké 2023
2023-03-01 - Kvartalsrapport 2023-Q3
2022-12-01 - Kvartalsrapport 2023-Q2
2022-10-03 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2022-09-28 - Årsstämma
2022-08-31 - Kvartalsrapport 2023-Q1
2022-06-10 - Bokslutskommuniké 2022
2022-03-02 - Kvartalsrapport 2022-Q3
2021-12-02 - Kvartalsrapport 2022-Q2
2021-09-09 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2021-09-02 - Kvartalsrapport 2022-Q1
2021-05-31 - Bokslutskommuniké 2021
2021-03-03 - Kvartalsrapport 2021-Q3
2020-12-02 - Kvartalsrapport 2021-Q2
2020-09-30 - Årsstämma
2020-09-09 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2020-08-24 - Kvartalsrapport 2021-Q1
2020-06-08 - Bokslutskommuniké 2020
2020-04-20 - Extra Bolagsstämma 2020
2020-03-02 - Kvartalsrapport 2020-Q3
2019-12-02 - Kvartalsrapport 2020-Q2
2019-09-30 - Årsstämma
2019-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2019-09-02 - Kvartalsrapport 2020-Q1
2019-06-10 - Bokslutskommuniké 2019
2019-03-04 - Kvartalsrapport 2019-Q3
2018-12-17 - Kvartalsrapport 2019-Q2
2018-09-25 - X-dag ordinarie utdelning INTEG B 0.00 SEK
2018-09-24 - Årsstämma
2018-09-24 - Kvartalsrapport 2019-Q1
2018-06-25 - Bokslutskommuniké 2018
2018-03-26 - Kvartalsrapport 2018-Q3
2017-12-18 - Kvartalsrapport 2018-Q2
2017-09-25 - Årsstämma
2017-09-25 - Kvartalsrapport 2018-Q1
2017-06-30 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Integrum är verksamt inom medicinteknik. Idag utvecklar bolaget system för skelettförankrade proteser baserat på det framtagna OPRA-implantatsystemet, som senare vidaresäljs till sjukhus världen över. Implantatet sätts på patientens ben med hjälp utav titanskruvar och antas förbättra livet för en stor del patienter med amputation. Bolaget grundades 1998 och har sitt huvudkontor i Mölndal.
2020-08-26 14:30:00

Patients at Emory Healthcare now have access to the OPRA™ Implant system for above-knee amputations.

Emory Healthcare (https://www.emoryhealthcare.org/), the largest healthcare system in the state of Georgia with 11 hospitals and 250 provider locations, has launched a new Osseointegration Program with Integrum's OPRA™ Implant System. The program is led by Nickolas Reimer, MD, (https://providers.emoryhealthcare.org/provider/Nickolas+Bernard+Reimer/780149) and Shervin Oskouei, MD (https://providers.emoryhealthcare.org/provider/Shervin+V+Oskouei/778866),  specialists in orthopaedic oncology and orthopaedic surgery.

Integrum's OPRA™ Implant System (https://integrum.se/opra-implant-system/) is the only FDA-approved, bone-anchored prosthetic solution available in the United States. OPRA™ Implant System consists of an anchorage element (fixture) and a skin penetrating device (abutment). The fixture is surgically inserted into the femur, and after a healing time of several months, the abutment is connected to the fixture. The prosthetic leg is then attached directly to the abutment via the OPRA™ Axor™, a prosthetic connection and safety device.

"We're excited to introduce this new technology to our patients to advance their limb function and improve their quality of life," says Scott D. Boden, MD (https://providers.emoryhealthcare.org/provider/Scott+D+Boden/779092), vice president for business innovation for Emory Healthcare and professor and chair of the Department of Orthopaedics, Emory University School of Medicine.

Over the past years, the introduction and consideration of osseointegration as a viable option for specific amputees within the limb loss community has continued to establish itself in the U.S. market. This rapidly developing treatment for amputee care gained a considerable boost when the FDA awarded Integrum an HDE approval for the OPRA™ Implant System in July 2015. The subsequent years have seen the Department of Defense, University of California San Francisco, Johns Hopkins Hospital, and Presbyterian St.Luke's Medical Center Hospital adopt the OPRA™ Implant System.

Blake Pokress, Vice President of Integrum Inc added, "We are excited to see Emory Healthcare adopt our technology through our partners at Onkos Surgical (https://onkossurgical.com/). We strive to make this remarkable technology accessible for individuals living with limb loss in the United States, and this is another step towards that".

To make an appointment at Emory Orthopaedics & Spine Center (https://www.emoryhealthcare.org/centers-programs/orthopedic-spine-center/index.html?utm_source=print&utm_campaign=default&utm_medium=short-url&utm_content=ortho), call 404-778-3350.

[image]

The information in this press release is information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out below, at 14:30 CET on August 26[th], 2020.Integrum AB is listed on Nasdaq First North in Stockholm. Erik Penser is the Company's Certified Adviser.